Cerebrolysin vs Semax

Overview

Cerebrolysin and semax are both positioned as neuroprotective agents but differ fundamentally in their composition and origin. Cerebrolysin is a complex mixture of peptides derived from porcine brain tissue, while semax is a synthetic heptapeptide based on ACTH. Both are approved in some countries but not by the FDA.

This comparison matters because both are discussed in cognitive enhancement and neurological recovery contexts, with different evidence bases and regulatory statuses.

Key Facts

Aspect	Cerebrolysin	Semax
Composition	Peptide mixture (porcine brain)	Single synthetic peptide
Structure	Multiple peptides + amino acids	7 amino acids (ACTH 4-7 + PGP)
Origin	Austria (EVER Pharma)	Russia (Institute of Molecular Genetics)
Administration	IV/IM injection	Intranasal
FDA Status	Not approved	Not approved

Composition Differences

Aspect	Cerebrolysin	Semax
Type	Complex biological mixture	Defined synthetic compound
Source	Porcine brain enzymatic hydrolysis	Chemical synthesis
Components	Thousands of peptides, amino acids	Single 7-AA peptide
Standardization	Batch-to-batch variation possible	Consistent composition

Cerebrolysin Composition

• Derived from pig brain tissue
• Enzymatically processed
• Contains peptides 200-10,000 Da
• ~25% low molecular weight peptides
• ~75% free amino acids
• Active components not fully characterized

Semax Structure

• Met-Glu-His-Phe-Pro-Gly-Pro
• ACTH(4-7) fragment + Pro-Gly-Pro tail
• PGP tail increases stability
• Defined, reproducible structure

Mechanism Comparison

Aspect	Cerebrolysin	Semax
Primary Mechanism	Neurotrophic mimetic	BDNF/melanocortin modulation
Growth Factor Effects	BDNF-like, NGF-like	Increases endogenous BDNF
Neuroprotection	Claimed	Claimed
Defined Target	Multiple (unclear)	Partially characterized

Cerebrolysin Proposed Mechanisms

1. Neurotrophic Support

   • Mimics BDNF effects
   • Mimics NGF effects
   • Supports neuronal survival

2. Synaptic Effects

   • Promotes synaptic plasticity
   • Enhances neurotransmission
   • Supports dendritic branching

3. Metabolic Support

   • Improves glucose utilization
   • Enhances mitochondrial function
   • Reduces oxidative stress

Semax Proposed Mechanisms

1. BDNF Expression

   • Increases endogenous BDNF
   • Supports neuroplasticity
   • Neuroprotective effects

2. Melanocortin System

   • ACTH-related effects
   • Without hormonal activity
   • Cognitive modulation

3. Dopaminergic Effects

   • May affect dopamine pathways
   • Attention and cognition
   • Neuroprotective

Evidence Comparison

Factor	Cerebrolysin	Semax
Human Trials	Multiple (international)	Some (primarily Russian)
Cochrane Reviews	Yes (stroke, dementia)	No
Western Peer Review	More	Less
Independent Replication	Some	Limited

Cerebrolysin Evidence

Condition	Evidence Level	Notes
Stroke recovery	Low-Moderate	Mixed trial results
Alzheimer’s disease	Low	Some positive signals
Traumatic brain injury	Low	Limited controlled data
Vascular dementia	Low	Studied

Cochrane Review (2020) on Stroke:

• Concluded insufficient evidence for efficacy
• Called for larger, better-designed trials
• Safety appeared acceptable

Semax Evidence

Condition	Evidence Level	Notes
Cognitive enhancement	Low (Russian trials)	Methodology concerns
Stroke (Russia)	Low	Approved indication
ADHD (Russia)	Low	Pediatric use
Western validation	Very Low	Limited research

Clinical Applications

Cerebrolysin Approved Uses (Non-US)

Indication	Regions	Notes
Stroke	Europe, Asia	Recovery phase
Dementia	Some countries	Various types
Traumatic Brain Injury	Limited	Off-label/research

Semax Approved Uses (Russia)

Indication	Notes
Cognitive disorders	Primary indication
Stroke recovery	Approved
ADHD (pediatric)	Approved in Russia
Optic nerve atrophy	1% solution

Administration Comparison

Aspect	Cerebrolysin	Semax
Route	IV or IM injection	Intranasal drops
Course Length	10-30 days typical	Weeks to months
Convenience	Low (injection)	High (nasal spray)

Side Effect Profiles

Cerebrolysin

Effect	Frequency	Notes
Injection site reactions	Common	Expected
Dizziness	Occasional	Usually mild
Headache	Occasional	Transient
Agitation	Rare	Dose-dependent
Allergic reactions	Rare	Biological product

Semax

Effect	Frequency	Notes
Nasal irritation	Common	Route-related
Headache	Occasional	Usually mild
Dizziness	Occasional	Transient
Generally well-tolerated	Yes	Per Russian data

Safety Considerations

Factor	Cerebrolysin	Semax
Long-term data	Limited	Limited
Prion concerns	Theoretical (porcine)	None
Immunogenicity	Possible	Unlikely
Drug interactions	Unknown	Unknown

Cerebrolysin-Specific Concerns

Issue	Consideration
Animal-derived	Theoretical prion risk
Complex mixture	Undefined active components
Batch variation	Quality consistency
IV administration	Infection risk

Regulatory Status

Aspect	Cerebrolysin	Semax
FDA Status	Not approved	Not approved
European Approval	Yes (some countries)	No
Russian Approval	Yes	Yes
Asian Approval	Yes (several countries)	No
US Availability	Research/import	Research chemical

Why Not FDA Approved

Cerebrolysin:

• Insufficient controlled trial evidence
• Complex mixture difficult to standardize
• FDA would require new trials
• Commercial pathway unclear

Semax:

• Russian trials don’t meet FDA standards
• No Western pharmaceutical development
• Limited independent validation
• No commercial sponsor

Quality and Sourcing

Factor	Cerebrolysin	Semax
Pharmaceutical Grade	Available (Europe, Asia)	Russia only
Research Chemical	Yes	Yes
Quality Assurance	GMP (pharma)	Variable
Import Concerns	Possible	Common

Summary

Factor	Cerebrolysin	Semax
Composition	Complex mixture	Single peptide
Administration	IV/IM injection	Intranasal
Evidence Level	Moderate	Moderate
Western Research	More	Less
Approvals	Multiple countries	Russia only
Convenience	Low	High
Mechanism Clarity	Less defined	Partially defined

Key Takeaways

1. Fundamentally different: Cerebrolysin is a complex mixture; semax is a defined peptide
2. Neither FDA-approved: Both lack US regulatory approval
3. Cerebrolysin has more international use: Approved in multiple countries outside US
4. Semax is Russia-limited: Approval only in Russia
5. Evidence is limited for both: Neither has robust Phase 3 data by Western standards
6. Administration differs: Cerebrolysin requires injection; semax is intranasal
7. Semax is more convenient: Self-administered nasal spray vs. medical injection
8. Cerebrolysin concerns: Animal-derived product with undefined components

---

This comparison is for educational purposes only. Neither compound is FDA-approved. Cerebrolysin is approved in some countries. Semax is approved only in Russia.